Q1 2026 NeuroOne Medical Technologies Corp Earnings Call Transcript
Key Points
- NeuroOne Medical Technologies Corp (NMTC) reported a sequential increase in first-quarter sales, demonstrating positive momentum from fiscal year 2025.
- The company projects fiscal year 2026 sales to be at least $10.5 million, representing a minimum 17% increase from fiscal year 2025.
- The 1RF brain ablation system showed significant market penetration, with nearly half of all ablations performed since its launch occurring in fiscal Q1 2026.
- The OneRF trigeminal nerve ablation system received FDA 510(k) clearance and reported successful pain relief in initial patients, indicating promising clinical outcomes.
- NeuroOne Medical Technologies Corp (NMTC) accelerated its drug delivery program, expecting devices for commercial use and investigational studies six months earlier than planned.
- First-quarter product revenue decreased to $2.9 million from $3.3 million in the same quarter of fiscal 2025, reflecting a decline from the initial stocking order.
- The company reported a net loss of $1.4 million in the first quarter of 2026, compared to a net income of $1.8 million in the same quarter of the prior year.
- Product gross profit margin decreased to 54.2% from 58.9% in the same quarter of the prior fiscal year.
- Cash and cash equivalents decreased to $3.6 million as of December 30, 2025, from $6.6 million as of September 30, 2025.
- The company had no license revenue in the first quarter of fiscal 2026, compared to $3 million in the first quarter of fiscal 2025 from an expanded distribution agreement.
Good day, ladies and gentlemen, and welcome to the first quarter fiscal 2026 financial results conference call for NeuroOne Medical Technologies Corporation. Today's call will be conducted by the company's Chief Executive Officer, Dave Rosa, and Ron McClurg, the company's Chief Financial Officer.
Before I turn the call over to Mr. Rose, I'd like to remind you that this conference call will include forward-looking statements within the meaning of US federal securities laws with respect to future operations financial results, including our 2026 revenue guidance, events, trends and performance, which are based on management's beliefs and assumptions as of today's call.
Forward-looking statements may involve known and unknown risks, uncertainties and other factors, which may cause actual results to differ materially from those expressed or implied by such statements. See NeuroOne's financial results press release and SEC filings for information regarding specific risks and uncertainties that could cause actual results to differ. Except as required by law, NeuroOne undertakes no obligation to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
